Or Refractory Multiple Myeloma

• CLINICAL_TRIALS trial_result · 2023-04-10
  Clinical Trial Update: Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

  Clinical trial update for ABT-199 in relapsed or refractory multiple myeloma (Phase 1/Phase 2) with completed status and results posted.

• CLINICAL_TRIALS trial_result · 2021-04-01
  Clinical Trial Update: Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) [Phase 2]

  Phase 2 study of vorinostat combined with bortezomib in relapsed or refractory multiple myeloma completed; results posted in 2021.

• CLINICAL_TRIALS trial_result · 2021-01-08
  Clinical Trial Update: A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers [Phase 2]

  Phase 2 trial of carfilzomib plus dexamethasone in relapsed or refractory multiple myeloma was terminated at US community oncology centers; …

• CLINICAL_TRIALS trial_result · 2020-12-17
  Clinical Trial Update: A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. [Phase 1, Phase 2]

  A Phase I/Ib-II study to determine the maximum tolerated dose of AUY922 alone and with bortezomib, with or without dexamethasone, in relapse…

• CLINICAL_TRIALS trial_result · 2017-10-30
  Clinical Trial Update: Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide [Phase 2]

  A Phase II multicenter, open-label, single-arm study evaluating pomalidomide with dexamethasone and cyclophosphamide in relapsed or refracto…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.